Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | FABP7 | O15540 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21950699 | 0.92 | KMT2A (0.46) | FABP5KMT2AFABP7EPHX2CASP3 | |
| SCHEMBL31278102 | 0.92 | KMT2A (0.46) | FABP5KMT2AFABP7EPHX2CASP3 | |
| SCHEMBL31170925 | 0.90 | KMT2A (0.45) | FABP5KMT2AFABP7EPHX2CASP3 | |
| SCHEMBL800081 | 0.90 | KMT2A (0.45) | FABP5KMT2AFABP7EPHX2CASP3 | |
| SCHEMBL831614 | 0.90 | KMT2A (0.45) | FABP5KMT2AFABP7EPHX2CASP3 | |
| SCHEMBL31437116 | 0.90 | KMT2A (0.45) | FABP5KMT2AFABP7EPHX2CASP3 | |
| SCHEMBL29670345 | 0.90 | KMT2A (0.45) | FABP5KMT2AFABP7EPHX2CASP3 | |
| SCHEMBL4379819 | 0.89 | KMT2A (0.48) | FABP5KMT2AFABP7EPHX2CASP3 | |
| SCHEMBL38654751 | 0.89 | KMT2A (0.45) | FABP5KMT2AFABP7EPHX2CASP3 | |
| SCHEMBL15083344 | 0.89 | KMT2A (0.44) | FABP5KMT2AFABP7EPHX2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744668-A2 | POLYNUCLEOTIDE CONSTRUCTS | Sirius Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260085094-A1 | STAPLED PEPTIDE AND USE THEREOF | JIANGSU DEYUAN PHARMACEUTICAL CO LTD (CN) | 2026-03-26 | — | — | US | disclosed |
| US-20260027227-A1 | NOVEL THIOL REDUCTANT, METHOD AND USE THEREOF | SUZHOU BIOREINNO BIOTECHNOLOGY LTD COMPANY (CN) | 2026-01-29 | — | — | US | disclosed |
| US-20260001924-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | NEW YORK UNIVERSITY (US) | 2026-01-01 | — | — | US | disclosed |
| US-12509502-B2 | Hybrid immunoglobulin containing nonpeptidyl linkage | BIOMOLECULAR HOLDINGS LLC (US) | 2025-12-30 | — | — | US | disclosed |
| EP-3650464-B1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | SHANGPHARMA INNOVATION INC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250326815-A1 | STAPLE-CONTAINING POLYPEPTIDES AND APPLICATION THEREOF | SOTER BIOPHARMA PTE. LTD. (SG) | 2025-10-23 | — | — | US | disclosed |
| US-20250326775-A1 | A NOVEL THIOL REDUCTANT, PREPARATION METHOD AND USE THEREOF | SUZHOU BIOREINNO BIOTECHNOLOGY LTD COMPANY (CN) | 2025-10-23 | — | — | US | disclosed |
| US-20250320310-A1 | A METHOD FOR PROGRAMMATICALLY MANAGING ANTIBODY DISULFIDE BONDS SITE-SPECIFIC MODIFICATION | SUZHOU BIOREINNO BIOTECHNOLOGY LTD COMPANY (CN) | 2025-10-16 | — | — | US | disclosed |
| US-20250270255-A1 | CASPASE-2 INHIBITOR COMPOUNDS | KINTSUGI THERAPEUTICS S L (ES) | 2025-08-28 | — | — | US | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20070042450-A1 | Multi-transduction mechanism based microfluidic analyte sensors | WORCESTER POLYTECHNIC INSTITUTE (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070042450-A1 | Multi-transduction mechanism based microfluidic analyte sensors | WORCESTER POLYTECHNIC INSTITUTE (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070042450-A1 | Multi-transduction mechanism based microfluidic analyte sensors | WORCESTER POLYTECHNIC INSTITUTE (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2006113440-A2 | MULTI-TRANSDUCTION MECHANISM BASED MICROFLUIDIC ANALYTE SENSORS | WORCESTER POLYTECHNIC INSTITUTE (US) | 2006-10-26 | — | — | WO | disclosed |
| US-20040086949-A1 | Method for preparing a ligand presenting assembly (LPA), an LPA and uses thereof | STATENS SERUM INSTITUT | 2004-05-06 | — | — | US | disclosed |
| EP-1117677-B1 | LIGAND PRESENTING ASSEMBLY (LPA), METHOD OF PREPARATION AND USES THEREOF | STATENS SERUMINSTITUT (DK) | 2003-11-12 | — | — | EP | disclosed |
| EP-1117677-A1 | LIGAND PRESENTING ASSEMBLY (LPA), METHOD OF PREPARATION AND USES THEREOF | Statens Serum Institut (DK) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000018791-A1 | LIGAND PRESENTING ASSEMBLY (LPA), METHOD OF PREPARATION AND USES THEREOF | STATENS SERUM INSTITUT (DK) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027227-A1 | NOVEL THIOL REDUCTANT, METHOD AND USE THEREOF | CBR1, SCLY, SSB | FABP5 1014/4885KMT2A 4118/4885FABP7 1948/4885 |
| US-20250326775-A1 | A NOVEL THIOL REDUCTANT, PREPARATION METHOD AND USE THEREOF | TMT1A, TST, PRDX3 | FABP5 1564/4885KMT2A 2805/4885FABP7 1757/4885 |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | GALE, ENGASE, UGGT1 | FABP5 2355/4885KMT2A 1219/4885FABP7 2926/4885 |
| US-20250270255-A1 | CASPASE-2 INHIBITOR COMPOUNDS | CASP2, CASP1, CASP3 | FABP5 2685/4885KMT2A 2998/4885FABP7 3440/4885 |
| US-20250320310-A1 | A METHOD FOR PROGRAMMATICALLY MANAGING ANTIBODY DISULFIDE BONDS SITE-SPECIFIC MODIFICATION | PTMS, PDIA6, SCLY | FABP5 1966/4885KMT2A 1122/4885FABP7 3170/4885 |
| US-20250326815-A1 | STAPLE-CONTAINING POLYPEPTIDES AND APPLICATION THEREOF | VIP, IGFBP5, IGFBP1 | FABP5 159/4885KMT2A 4872/4885FABP7 334/4885 |
| US-20260085094-A1 | STAPLED PEPTIDE AND USE THEREOF | VIP, ARGLU1, NGLY1 | FABP5 3011/4885KMT2A 4388/4885FABP7 3254/4885 |
| US-20260001924-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | DDX21, PHAX, RBX1 | FABP5 2292/4885KMT2A 2849/4885FABP7 1763/4885 |
| US-12509502-B2 | Hybrid immunoglobulin containing nonpeptidyl linkage | FCGR2A, FCGR3B, CD74 | FABP5 66/4885KMT2A 3327/4885FABP7 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.